Drug Price Trends for GRANISETRON HCL

Average Pharmacy Cost for GRANISETRON HCL

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GRANISETRON HCL 1 MG TABLET	69452-0350-92	1.38870	EACH	2024-12-18
GRANISETRON HCL 1 MG TABLET	69452-0350-11	1.38870	EACH	2024-12-18
GRANISETRON HCL 1 MG TABLET	51991-0735-99	1.38870	EACH	2024-12-18
GRANISETRON HCL 1 MG TABLET	69452-0350-01	1.38870	EACH	2024-12-18
GRANISETRON HCL 1 MG TABLET	51991-0735-20	1.38870	EACH	2024-12-18

Granisetron HCL Market Analysis and Price Projections

Introduction to Granisetron HCL

Granisetron HCL is a potent antiemetic drug belonging to the 5HT3 receptor antagonists class. It is widely used to treat nausea and vomiting induced by chemotherapy, radiotherapy, and postoperative recovery. The market for granisetron HCL is driven by several key factors, including the rising incidence of cancer, advancements in healthcare infrastructure, and the increasing demand for effective antiemetic treatments.

Market Size and Growth Projections

The granisetron HCL market is expected to experience significant growth over the forecast period. Here are some key projections:

• The market is anticipated to register a Compound Annual Growth Rate (CAGR) of 5.7% to 6.2% from 2025 to 2030[1][4].
• In 2023, the granisetron hydrochloride market was valued at USD 1.4 billion and is projected to reach USD 2 billion by 2031, growing at a CAGR of 5.2% from 2024 to 2031[2].

Key Drivers of Market Growth

Rise in Chemotherapy and Radiotherapy Visits

The increasing burden of cancer globally is a major driver for the granisetron HCL market. According to GLOBOCAN estimates, the high incidence of cancer cases, such as the 2,281,658 new cancer cases diagnosed in the United States in 2020, indicates a rise in patient visits for chemotherapy and radiotherapy. This increase in treatments necessitates the use of antiemetic drugs like granisetron HCL, thereby driving market growth[4].

Increasing Prevalence of Gastroparesis

Gastroparesis, a condition characterized by delayed stomach emptying, is another factor contributing to the demand for granisetron HCL. The rising prevalence of this condition, along with other gastrointestinal disorders, adds to the market's growth potential[1][4].

Advancements in Healthcare Infrastructure

The global expansion of healthcare infrastructure and technological advancements in drug formulations are significant drivers. Improved access to healthcare services and the development of more efficient drug delivery systems enhance the market's growth prospects[2].

Geographical Market Analysis

North America

North America is expected to hold the largest share in the granisetron HCL market. The high burden of cancer cases, increased prevalence of gastroparesis, and the rise in adoption of granisetron among cancer patients in this region are key factors. For instance, the American Cancer Society estimated 2 million cancer cases to be diagnosed in the United States in 2024, up from 1.9 million in 2023[1].

Asia-Pacific

The Asia-Pacific region is anticipated to be the fastest-growing market for granisetron HCL. This growth is attributed to the increasing incidence of cancer, improving healthcare infrastructure, and rising healthcare expenditure in countries within this region[1][4].

Market Leaders and Competitive Landscape

The granisetron HCL market is semi-consolidated, with several major players operating globally and regionally. Key market leaders include:

• Kyowa Kirin Co., Ltd.
• Heron Therapeutics, Inc.
• Viatris
• Hikma Pharmaceuticals PLC
• Fresenius SE & Co. KGaA

These companies are involved in various strategic activities such as product launches, collaborations, and expansions to enhance their product portfolios[1].

Product Segments and Applications

Granisetron HCL is available in various formulations, including:

• Oral Tablets
• Injection Solutions
• Patch Formulations

The drug is used for several applications, including:

• Chemotherapy-Induced Nausea
• Postoperative Nausea
• Nausea and Vomiting

These diverse formulations and applications cater to different patient needs, contributing to the market's growth[2].

Price Analysis

The cost of granisetron HCL can vary based on the formulation and quantity. Here are some price points for reference:

• Intravenous Solution: The cost for granisetron (1 mg/mL) intravenous solution is around $20 for a supply of 1 milliliter, depending on the pharmacy[5].
• Oral Tablet: Prices for oral tablets also vary, but generally, they are priced competitively in the market.

Impact of COVID-19

The COVID-19 pandemic had a limited impact on the granisetron HCL market, primarily due to supply chain disruptions and the illness of healthcare workers. However, the pandemic did not significantly alter the long-term growth trajectory of the market[3].

Market Trends and Opportunities

High Healthcare Expenditure

High healthcare expenditure per capita and favorable medical reimbursement policies in developed nations have contributed to the growth of the granisetron HCL market. These factors enable more patients to access antiemetic treatments, driving market demand[3].

Increase in Personalized Medicine

The increasing demand for personalized medicine and over-the-counter (OTC) products presents opportunities for the granisetron HCL market. Manufacturers are focusing on developing more patient-centric care solutions, which is expected to boost market growth[3].

Technological Advancements

Advancements in drug delivery technologies and medical technology are improving the effectiveness and convenience of granisetron HCL. These innovations are crucial in enhancing patient compliance and overall treatment outcomes[2].

Challenges and Restraints

Side Effects

Granisetron HCL can have severe side effects such as anxiety, trouble sleeping, and drowsiness, which can restrain market growth. These side effects may lead to reduced patient compliance and alternative treatment options[3].

Key Takeaways

• The granisetron HCL market is expected to grow at a CAGR of 5.7% to 6.2% from 2025 to 2030.
• The market is driven by the rise in chemotherapy and radiotherapy visits, increasing prevalence of gastroparesis, and advancements in healthcare infrastructure.
• North America holds the largest market share, while the Asia-Pacific region is the fastest-growing market.
• Major players include Kyowa Kirin Co., Ltd., Heron Therapeutics, Inc., Viatris, Hikma Pharmaceuticals PLC, and Fresenius SE & Co. KGaA.
• The drug is available in various formulations and is used for multiple applications, including chemotherapy-induced nausea and postoperative nausea.

FAQs

What is the expected CAGR of the granisetron HCL market from 2025 to 2030?

The granisetron HCL market is expected to register a CAGR of 5.7% to 6.2% from 2025 to 2030[1][4].

Which region is expected to be the fastest-growing market for granisetron HCL?

The Asia-Pacific region is anticipated to be the fastest-growing market for granisetron HCL[1][4].

What are the primary applications of granisetron HCL?

Granisetron HCL is primarily used for chemotherapy-induced nausea, postoperative nausea, and other forms of nausea and vomiting[2].

Who are the major players in the granisetron HCL market?

Major players include Kyowa Kirin Co., Ltd., Heron Therapeutics, Inc., Viatris, Hikma Pharmaceuticals PLC, and Fresenius SE & Co. KGaA[1].

How has the COVID-19 pandemic impacted the granisetron HCL market?

The COVID-19 pandemic had a limited impact on the granisetron HCL market, mainly due to supply chain disruptions and the illness of healthcare workers, but it did not significantly alter the long-term growth trajectory[3].

Sources

1. Mordor Intelligence: Granisetron Market Size & Share Analysis - Industry Research Report
2. Market Research Intellect: Granisetron Hydrochloride Market Size and Projections
3. Allied Market Research: Granisetron Market Size, Growth, Share, Industry Insight 2030
4. GI Research: Granisetron Market - Growth, Trends, and Forecasts (2023 - 2028)
5. Drugs.com: Granisetron Prices, Coupons, Copay Cards & Patient Assistance